UY35441A - Agentes quelantes de precursores de producto final de glicación avanzada (age). - Google Patents
Agentes quelantes de precursores de producto final de glicación avanzada (age).Info
- Publication number
- UY35441A UY35441A UY0001035441A UY35441A UY35441A UY 35441 A UY35441 A UY 35441A UY 0001035441 A UY0001035441 A UY 0001035441A UY 35441 A UY35441 A UY 35441A UY 35441 A UY35441 A UY 35441A
- Authority
- UY
- Uruguay
- Prior art keywords
- age
- precursors
- glication
- advanced
- final product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35441A true UY35441A (es) | 2014-10-31 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035441A UY35441A (es) | 2013-03-15 | 2014-03-14 | Agentes quelantes de precursores de producto final de glicación avanzada (age). |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (enExample) |
| EP (1) | EP2968403A1 (enExample) |
| JP (4) | JP2016512830A (enExample) |
| KR (1) | KR20150130492A (enExample) |
| CN (1) | CN105188718A (enExample) |
| AR (1) | AR095593A1 (enExample) |
| AU (2) | AU2014235500A1 (enExample) |
| BR (1) | BR112015023404A8 (enExample) |
| CA (1) | CA2906501A1 (enExample) |
| CL (1) | CL2015002624A1 (enExample) |
| CR (1) | CR20150545A (enExample) |
| DO (1) | DOP2015000221A (enExample) |
| EA (1) | EA201591733A1 (enExample) |
| HK (1) | HK1220607A1 (enExample) |
| IL (1) | IL241406A0 (enExample) |
| MA (1) | MA38487A1 (enExample) |
| MX (1) | MX2015012843A (enExample) |
| PE (1) | PE20151766A1 (enExample) |
| PH (1) | PH12015502019A1 (enExample) |
| SG (2) | SG11201506413PA (enExample) |
| TN (1) | TN2015000390A1 (enExample) |
| TW (1) | TW201521744A (enExample) |
| UY (1) | UY35441A (enExample) |
| WO (1) | WO2014150873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| BR112020003638A2 (pt) * | 2017-08-31 | 2020-09-01 | Cytosorbents Corporation | redução de produtos finais de glicação avançada a partir de fluidos corporais |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| ES2637020T3 (es) * | 2001-04-18 | 2017-10-10 | Genzyme Corporation | Uso de polímero de amina para reducir la glucosa sérica |
| AU2003263010A1 (en) * | 2003-09-02 | 2005-04-21 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| JP2007523908A (ja) * | 2004-02-17 | 2007-08-23 | ダイナミス セラピューティクス インコーポレイテッド | フルクトサミン３キナーゼ並びにコラーゲン及びエラスチンの形成 |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| US9181364B2 (en) * | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
-
2014
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en not_active Ceased
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Withdrawn
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 HK HK16108617.8A patent/HK1220607A1/zh unknown
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en not_active Withdrawn
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150545A (es) | 2015-12-01 |
| SG11201506413PA (en) | 2015-09-29 |
| EP2968403A1 (en) | 2016-01-20 |
| JP2018135365A (ja) | 2018-08-30 |
| PH12015502019A1 (en) | 2016-01-11 |
| BR112015023404A2 (pt) | 2017-07-18 |
| BR112015023404A8 (pt) | 2019-12-03 |
| CA2906501A1 (en) | 2014-09-25 |
| MX2015012843A (es) | 2016-08-08 |
| AU2014235500A1 (en) | 2015-11-05 |
| US20160024233A1 (en) | 2016-01-28 |
| EA201591733A1 (ru) | 2016-01-29 |
| HK1220607A1 (zh) | 2017-05-12 |
| KR20150130492A (ko) | 2015-11-23 |
| CN105188718A (zh) | 2015-12-23 |
| TN2015000390A1 (en) | 2017-01-03 |
| PE20151766A1 (es) | 2015-12-11 |
| SG10201707590XA (en) | 2017-11-29 |
| TW201521744A (zh) | 2015-06-16 |
| CL2015002624A1 (es) | 2016-03-11 |
| US20180265613A1 (en) | 2018-09-20 |
| MA38487A1 (fr) | 2017-12-29 |
| DOP2015000221A (es) | 2015-12-15 |
| JP2022037143A (ja) | 2022-03-08 |
| JP2020055850A (ja) | 2020-04-09 |
| AR095593A1 (es) | 2015-10-28 |
| JP2016512830A (ja) | 2016-05-09 |
| IL241406A0 (en) | 2015-11-30 |
| WO2014150873A1 (en) | 2014-09-25 |
| AU2019201259A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
| UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
| MX2018013099A (es) | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido. | |
| TW201613901A (en) | New compounds | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| EA201890204A1 (ru) | Антибактериальные соединения | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| MX2015007936A (es) | Inhibidores de autotaxina. | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| UY34859A (es) | Análogos peptídicos de la exendina 4. | |
| UY34616A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| PE20151746A1 (es) | Compuestos biciclicos | |
| MX381944B (es) | Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos. | |
| GEP201606566B (en) | Isoxazolidine derivatives | |
| MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
| PH12017501695A1 (en) | Treatment of type 2 diabetes mellitus patients | |
| UY35441A (es) | Agentes quelantes de precursores de producto final de glicación avanzada (age). | |
| EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| EA201690938A1 (ru) | Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания | |
| CY1118614T1 (el) | Νεα παραγωγα (αζα)βενζυδρυλαιθερα, διεργασια παρασκευης τους και χρηση τους ως προσδετες h4-υποδοχεα για θεραπευτικες εφαρμογες | |
| EA201892349A1 (ru) | Композиции, содержащие экстракт почек тополя, и их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211112 |